CDT Equity (CDT) Preferred Stock Liabilities (2022 - 2023)
CDT Equity's (CDT) quarterly Preferred Stock Liabilities came in at $23.1 million in Q2 2023, down 82.88% YoY from $135.0 million in Q2 2022, and up 1.08% on a QoQ basis from $22.9 million in Q1 2023.
CDT Equity (CDT) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
CDT Equity (CDT) has 2 years of Preferred Stock Liabilities data on file, last reported at $23.1 million in Q2 2023.
- Quarterly Preferred Stock Liabilities fell 82.88% year-over-year to $23.1 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $23.1 million (down 82.88% YoY) and the FY2022 annual result came in at $136.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $23.1 million in Q2 2023, from $22.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $136.8 million in Q4 2022 to a low of $22.9 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 23.11 Mn |
| Mar 31, 2023 | 22.86 Mn |
| Dec 31, 2022 | 136.77 Mn |
| Sep 30, 2022 | 135.61 Mn |
| Jun 30, 2022 | 135.00 Mn |
| Mar 31, 2022 | 134.90 Mn |